Yang Yeon-ho

Bridge Biotherapeutics Inc. gave its first presentation at the Main Track of J.P. Morgan Healthcare Conference, the most informative healthcare symposium in the industry, as well as revealing promising clinical data for its idiopathic pulmonary fibrosis (IPF) drug candidate, BBT-877. The drugmaker began a Phase 2 clinical trial for the drug candidate for IPF, a rare lung disease that causes lung stiffening. The trial is in its final stages, with topline data expected in April 2025.

South Korea’s Celltrion has declared its ambitions to become a global leader in innovative drug development, with plans to accelerate its pipeline of next-generation antibody-drug conjugates (ADCs) and bispecific antibodies.

Samyang Foods Inc. has announced plans to expand into the microbiome business, focusing on gut microbiota transplantation technology as its first venture in the sector. The move aligns with the company’s strategy to position biotechnology as a core driver of growth. The initiative is expected to leverage synergies between its existing food and healthcare businesses.